Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

An experimental COVID-19 treatment hit the mark in an 800-patient clinical trial.

Eli Lilly Reports Success With COVID-19 Neutralizing Antibody Treatment

Eli Lilly stock is climbing slightly higher Wednesday after it became the first company to release antibody drug results. 
The post Eli Lilly Stock Looks Hot on New Antibody Drug Evidence appeared first on InvestorPlace.

Eli Lilly Stock Looks Hot on New Antibody Drug Evidence

Lilly's (LLY) EMPACT-MI study is part of Jardiance's ENPOWER clinical program, which is studying the impact of Jardiance on major clinical cardiovascular and renal outcomes in a spectrum of cardio-renal-metabolic conditions.

Lilly Drug Gets Fast Track to Improve Heart Attack Outcome

Eli Lilly released positive data from a test of a Covid-19 treatment, the second time in three days it's posted positive data on a possible Covid-19 treatment, and Eli Lilly stock rose early.
The post Eli Lilly Posts Positive Data On Covid-19 Treatment In Phase 2 Trials appeared first on Investor's Business Daily.

Eli Lilly Posts Positive Data On Covid-19 Treatment In Phase 2 Trials

Shares of Eli Lilly & Co. LLY, +0.72% gained 2.6% in premarket trading on Tuesday after the drug maker said interim data from a mid-stage clinical trial assessing its experimental antibody treatment reduced the rate of hospitalization as well as viral load in some COVID-19 patients.

Shares of Lilly gain as it discloses promising interim findings for COVID-19 antibody treatment

Eli Lilly announced on Wednesday it had found proof of concept data from an interim analysis of the BLAZE-1 clinical trial that showed a reduced rate of hospitalization for coronavirus patients treated with its neutralizing antibody drug.

Eli Lilly reports a reduced rate of hospitalization for coronavirus patients using its antibody treatment

INDIANAPOLIS, Sept. 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced proof of concept data from an interim analysis of the BLAZE-1 clinical trial, showing a reduced rate of hospitalization for patients treated with LY-CoV555.

Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

Eli Lilly (LLY) releases positive initial data from a phase III study evaluating Olumiant (baricitinib) in combination with Gilead's remdesivir for hospitalized patients with COVID-19.

Lilly's Olumiant Meets Primary Endpoint in Coronavirus Study

INDIANAPOLIS, Sept. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has launched an open innovation challenge for individuals and teams across the United States to submit inspiring digital health solutions that can help make life better for people living with atopic dermatitis.

Lilly Launches Digital Health Open Innovation Challenge to Help Transform Atopic Dermatitis Care

Gilead Sciences

Pfizer

Major coronavirus treatments and vaccine maker executives were interviewed on CNBC Monday to discuss their company's progress in the battle against the disease.

Gilead, Pfizer, Eli Lilly CEOs On COVID-19 Treatments, Vaccine Development

Immunomedics

Incyte

Merck

Seagen

M&A Activities Intensify in Pharma Industry.

M&A Activities Intensify in Pharma Industry

Merck, Gilead and Lilly make progress on an otherwise slow news day.

No Econ Data, but Big Biopharma News

Eli Lilly and Incyte released positive initial data of their coronavirus treatment when combined with Gilead's remdesivir and said they would seek emergency use authorization from the FDA.
The post Eli Lilly, Incyte Combine Covid Drug With Gilead's, Post Positive Data appeared first on Investor's Business Daily.

Eli Lilly, Incyte Combine Covid Drug With Gilead's, Post Positive Data

Eli Lilly said on Monday its rheumatoid arthritis drug baricitinib shortened the time taken to recover from Covid-19 in hospitalized patients when taken in combination with Gilead Sciences Inc's antiviral remdesivir.

Eli Lilly's rheumatoid arthritis drug helps recovery in coronavirus patients

Eli Lily & Co. LLY, +1.27% and Incyte Corp. INCY, -0.29% said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was used in combination with Gilead Sciences Inc.

Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time

SAN FRANCISCO and SUZHOU, China, Sept. 14, 2020 /PRNewswire/ -- Innovent Biologics, Inc.

Innovent and Lilly Jointly Announce Results of Six Clinical Studies of TYVYT® (sintilimab injection) to be Presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020

INDIANAPOLIS, Sept. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020.

Lilly to Participate in Cantor Fitzgerald Virtual Global Healthcare Conference

INDIANAPOLIS, Sept. 11, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, September 16, 2020.

Lilly to Participate in Morgan Stanley Global Healthcare Conference

Pfizer’s stock has gained 28% since the March 23 lows of this year, in-line with Eli Lilly & Company stock, which has gained 29% of its value. The lockdown in various parts of the world has had a negative impact on the pharmaceuticals industry worldwide due to deferment of elective surgeries.

Eli Lilly Stock A Better Bet Compared To Pfizer

INDIANAPOLIS, Sept. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 21, 2020 to discuss the company's presentations at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress.

Lilly Announces Webcast to Discuss ESMO 2020 Presentations

INDIANAPOLIS, Sept. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), which introduced the Lilly Insulin Value Program $35 copay card in April 2020 to help people struggling financially during the COVID-19 crisis, today announced the program has been added to the company's.

Lilly commits Insulin Value Program, featuring $35 copay card, to suite of affordability solutions for people with diabetes

Kamada

Eli Lilly and Kamada are two of the most intriguing companies working on this part of the COVID-19 problem.

2 Coronavirus Treatment Stocks to Buy Right Now

INDIANAPOLIS, Sept. 9, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Patrik Jonsson, senior vice president and president of Lilly Bio-Medicines, is being named to the new role of senior vice president, president of Lilly USA, and Chief Customer Officer.

Lilly Announces Leadership Changes

AstraZeneca

Horizon Pharma

Dr. Reddy's Labs

Repligen

Zoetis

The pandemic isn't the only reason you should be looking a pharmaceutical stocks. Here are six pharma companies that stand out with or without Covid-19.

6 of the Best Pharmaceutical Stocks to Buy Today

Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.

News for Eli Lilly Stock (LLY)